Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
Dhruv Bansal, Melissa A. Reimers, E Knoche, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 334-334
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Sonodynamical reversion of immunosuppressive microenvironment in prostate cancer via engineered exosomes
Dingyi Wang, Zhuo Wan, Qian Yang, et al.
Drug Delivery (2022) Vol. 29, Iss. 1, pp. 702-713
Open Access | Times Cited: 43
Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis
Shenglong Li, Yue Kang, Yu Zeng
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1879, Iss. 1, pp. 189033-189033
Closed Access | Times Cited: 41
Recent advances and future perspectives in the therapeutics of prostate cancer
Ganji Lakshmi Varaprasad, Vivek Gupta, K. Satya Prasad, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 27
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Atish D. Choudhury, Lucia Kwak, Alexander Cheung, et al.
Cancer Immunology Research (2024) Vol. 12, Iss. 6, pp. 704-718
Open Access | Times Cited: 15
The tumor microenvironment and immune responses in prostate cancer patients
J. Kwon, Richard J. Bryant, Ellen Parkes
Endocrine Related Cancer (2021) Vol. 28, Iss. 8, pp. T95-T107
Open Access | Times Cited: 55
Green Metallic Nanoparticles for Cancer Therapy: Evaluation Models and Cancer Applications
Ernesto Tinajero‐Díaz, Daniela Salado‐Leza, Carmen González, et al.
Pharmaceutics (2021) Vol. 13, Iss. 10, pp. 1719-1719
Open Access | Times Cited: 50
mRNA vaccines in the prevention and treatment of diseases
Yangzhuo Gu, Jiangyao Duan, Na Yang, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 37
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives
Sara Elena Rebuzzi, Pasquale Rescigno, Fabio Catalano, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1245-1245
Open Access | Times Cited: 35
Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer
Dechao Feng, Qiao Xiong, Facai Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 34
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer
Rebecca Garnham, Daniel Geh, Ryan Nelson, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 8
Role of Lipids and Lipid Metabolism in Prostate Cancer Progression and the Tumor’s Immune Environment
Aino Siltari, Heimo Syvälä, Yan‐Ru Lou, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4293-4293
Open Access | Times Cited: 28
Icariin inhibits prostate cancer bone metastasis and destruction via suppressing TAM/CCL5-mediated osteoclastogenesis
Chiwei Chen, Shengqi Wang, Neng Wang, et al.
Phytomedicine (2023) Vol. 120, pp. 155076-155076
Closed Access | Times Cited: 13
CD8 + T cell targeting of tumor antigens presented by HLA-E
Ravi Iyer, Marieke C. Verweij, Sujit S. Nair, et al.
Science Advances (2024) Vol. 10, Iss. 19
Open Access | Times Cited: 5
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment
Andrea Palicelli, Stefania Croci, Alessandra Bisagni, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 22, pp. 12330-12330
Open Access | Times Cited: 28
Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer
Weian Zhu, Hengda Zeng, Jiongduan Huang, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 11
Fu-Zheng-Yi-Liu Formula inhibits the stem cells and metastasis of prostate cancer via tumor-associated macrophages/C-C motif chemokine ligand 5 pathway in tumor microenvironment
Chiwei Chen, Renlun Huang, Neng Wang, et al.
Chinese Journal of Natural Medicines (2024) Vol. 22, Iss. 6, pp. 501-514
Closed Access | Times Cited: 4
The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer
Jiao Ma, Liang Yu, Jiangchu Yangqing, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
The application of emerging immunotherapy in the treatment of prostate cancer: progress, dilemma and promise
Jizhong Che, Yuanyuan Liu, Yangyang Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Therapeutic effects of NK cell-derived EVs on cancer: Current advances and future treatment strategies
Mehtap Kızılpınar, Mohammadreza Dastourı
(2025) Vol. 2, Iss. 1, pp. 10-24
Closed Access
Transcriptomic analysis of human Castration-Resistant prostate cancer: insights into novel therapeutic strategies
G. Ramanjaneyulu, Sneha Jaiswal, Anaswara Jayan, et al.
Computational Biology and Chemistry (2025), pp. 108459-108459
Closed Access
Identification of the gene signatures related to NK/T cell communication to evaluate the tumor microenvironment and prognostic outcomes of patients with prostate adenocarcinoma
Kun Zhang, Huyang Xie, Fan Zhao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications
Erfan Rezazadeh‐Gavgani, Reza Majidazar, Parisa Lotfinejad, et al.
Immunity Inflammation and Disease (2025) Vol. 13, Iss. 4
Open Access
Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature
Davide Bimbatti, Marco Maruzzo, Francesco Pierantoni, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 170, pp. 103579-103579
Closed Access | Times Cited: 17
Microwave triggered multifunctional nanoplatform for targeted photothermal-chemotherapy in castration-resistant prostate cancer
Pengyuan Liu, Yajun Wu, Xiaogang Xu, et al.
Nano Research (2023) Vol. 16, Iss. 7, pp. 9688-9700
Closed Access | Times Cited: 10
Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances
Miyad Movassaghi, Rainjade Chung, Christopher B. Anderson, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4757-4757
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top